To compare the incidence of hypertension and edema associated with the potent, oral COX-2 specific inhibitor, valdecoxib, versus the non-specific NSAIDs, we pooled data from all arthritis studies completed prior to February, 2001. These comprised 9 controlled rheumatoid arthritis (RA) and osteoarthritis (OA) trials of 6 -26 weeks duration, 7 of which had placebo-control groups. Edema and hypertension results were analyzed for patients receiving placebo (nϭ1142), valdecoxib 10 mg (the daily dose recommended for treating arthritis in the US; nϭ1543), 20 mg (nϭ1519), 40 mg (nϭ667) or NSAIDs (naproxen 500 mg BID, diclofenac 75 mg BID, and ibuprofen 800 mg TID; nϭ1846). The crude incidence of hypertension and edema was evaluated and compared with placebo and NSAIDs. Valdecoxib 10 mg or 20 mg daily was associated with an incidence of hypertension similar to placebo. The incidence of hypertension was significantly greater with valdecoxib 40 mg daily than with placebo but similar to NSAIDs (Table) . The incidence of edema with valdecoxib was significantly greater than placebo but similar to standard dosages of non-specific NSAIDs. These findings show that the incidence of hypertension following chronic treatment with valdecoxib at 10 or 20 mg daily is similar to placebo and to the standard non-specific NSAIDs. At a dose of 40 mg daily, the incidence of hypertension and edema was similar to the non-specific NSAIDs. These findings demonstrate that low and intermediate doses of valdecoxib appear to have an incidence of hypertension and edema similar to the non-specific NSAIDs. Sponsored by Pharmacia Corporation and Pfizer Inc.
P-447 CAN A LONG HALF-LIFE ANGIOTENSIN II BLOCKER HAVE GREATER EFFECTS ON THE CIRCADIAN VARIATION OF BLOOD PRESSURE?
William B. White. University of Connecticut School of Medicine, Farmington, CT.
Background:
Clinical trials have shown that small BP elevations increase cardiovascular (CV) risk. Furthermore, 24 hour and early morning BP are strongly linked to target organ damage and cardiovascular events. Thus, ideally antihypertensive drugs should induce both substantial reduction in 24 hour BP and have persistent clinical effects throughout the dosing period. In this study, we evaluated the impact of telmisartan (plasma half-life ϭ 24 hours) versus valsartan (plasma half-life ϭ 6-8 hours) using ambulatory blood pressure monitoring (ABPM) in over 450 patients.
Methods: This was a prospective, multicenter, double-blind, parallelgroup forced-titration trial in which patients were randomized to receive telmisartan (40 to 80 mg once daily) or valsartan (80 to 160 mg once daily) for a total of 8 weeks. Entry criteria included a seated clinic diastolic BP Ն 95 mm Hg and Յ109 mm Hg and a 24-hour ambulatory DBP Ն 85 mm Hg. The primary end point was the change from baseline in BP during the last 6 hours of the 24-hour dosing interval. Data were analyzed by analysis of covariance with baseline BP and drug treatment group as covariates.
Results: There were 456 patients randomized to either telmisartan or valsartan. The change from baseline in ambulatory diastolic BP during the last 6 hours was -7.7 Ϯ 0.6 mmHg for the telmisartan group (nϭ231) vs -5.7 Ϯ 0.6 mmHg for the valsartan group (nϭ225; P ϭ.01. The change from baseline for 24 hour systolic BP was -11.2 Ϯ 0.8 mmHg for telmisartan and -8.8 Ϯ 0.8 mmHg for valsartan (Pϭ.02). There were no differences in adverse events between the 2 groups.
Conclusion: These data show that telmisartan, the new angiotensin II receptor blocker with an inherently long plasma half-life had clinically and significantly greater reductions in ambulatory BP during the last 6 hours of the dosing interval than valsartan.
Key Words: 24 hour blood pressure, valsartan, telmisartan Purpose: Nonspecfic NSAIDs (NS NSAIDs) and COX-2 specific inhibitors are used by 66% of RA patients; the use of these drugs may be accompanied by potential, clinically important, renal side effects. Recently, a number of reports have suggested that rofecoxib may have more renal-related side effects than celecoxib and NS NSAIDs. In this report, we compared the difference in renal-related side effects among celecoxib, rofecoxib, and NS NSAIDs and investigated the burden of these sideeffects to RA patients.
P-448 PATIENT BURDEN OF WEIGHT GAIN AND BLOOD PRESSURE INCREASE AMONG RA PATIENTS USING CELECOXIB, ROFECOXIB, AND NON-SPECIFIC NSAIDS
Methods: In 2002, 2,595 patients who participated in a long-term outcomes study of RA and consequently used COX-2 specific inhibitors or NS NSAIDs were surveyed and grouped by their current NSAID: celecoxib (Nϭ822), rofecoxib (Nϭ448), naproxen (Nϭ276), ibuprofen (Nϭ226), aspirin (Nϭ176) and others (Nϭ647). Patients were assessed with a specially designed questionnaire to measure weight gain, swelling, and blood pressure increases. The questionnaire inquired about side effects and symptoms that were 'due to' NS NSAID or COX-2 specific inhibitor use. Questions were rated on 6-point categorical scales ranging from 'did not experience' to 'extremely bothered.' Ordered logistic regression and binary logistic regression, adjusting for 13 confounders, was used to distinguish the burden of side effects by treatment group. 
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